Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Mini Rev Med Chem ; 22(14): 1876-1894, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-33845740

RESUMEN

Coronavirus disease (CoVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) scrambles the world by infecting millions of peoples all over the globe. It has caused tremendous morbidity, mortality and greatly impacted the lives and economy worldwide as an outcome of mandatory quarantines or isolations. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in the clinical treatment of COVID-19 patients in large-scale studies. Physicians and researchers throughout the world are working to understand the pathophysiology to expose the conceivable handling regimens and to determine the effective vaccines and/or therapeutic agents. Some of them re-purposed drugs for clinical trials which were primarily known to be effective against the RNA viruses including MERS-CoV and SARS-CoV-1. In the absence of a proven efficacy therapy, the current management use therapies based on antivirals, anti-inflammatory drugs, convalescent plasma, anti-parasitic agents in both oral and parenteral formulation, oxygen therapy, and heparin support. What is needed at this hour, however, is a definitive drug therapy or vaccine. Different countries are rushing to find this, and various trials are already underway. We aimed to summarize the potential therapeutic strategies as treatment options for COVID-19 that could be helpful to stop further spread of SARS-CoV-2 by affecting its structural components or modulation of immune response and discuss the leading drugs/vaccines, which are considered as potential agents for controlling this pandemic.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , COVID-19 , Coronavirus del Síndrome Respiratorio de Oriente Medio , Antivirales/farmacología , Antivirales/uso terapéutico , COVID-19/terapia , Humanos , Inmunización Pasiva , Pandemias/prevención & control , SARS-CoV-2 , Sueroterapia para COVID-19
2.
Clin Exp Pharmacol Physiol ; 39(3): 274-82, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22004449

RESUMEN

1. Herba Leonuri, a traditional Chinese medicine, has a long history of development and application in China. In particular, Herba Leonuri has been widely used in the treatment of gynaecological and obstetric disorders for thousands of years. Recent studies have shown that Herba Leonuri has many different effects. 2. Herba Leonuri contains several active components, including alkaloids, flavonoids, diterpenes compounds and fatty acids. Recent studies have shown that these molecules exert beneficial effects in coronary artery disease and cerebral ischaemia. Thus, these molecules may become novel candidates for drug discovery and development. 3. The present review provides an overview of the chemical composition, with a focus on biological activity, of Herba Leonuri to stimulate new studies on traditional Chinese medicine.


Asunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/uso terapéutico , Leonurus , Medicina Tradicional China/métodos , Animales , Enfermedades Cardiovasculares/metabolismo , Medicamentos Herbarios Chinos/aislamiento & purificación , Flavonoides/química , Flavonoides/aislamiento & purificación , Flavonoides/uso terapéutico , Ácido Gálico/análogos & derivados , Ácido Gálico/química , Ácido Gálico/aislamiento & purificación , Ácido Gálico/uso terapéutico , Humanos , Rutina/química , Rutina/aislamiento & purificación , Rutina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA